Surveillance for hepatocellular carcinoma

被引:28
作者
Diaz-Gonzalez, Alvaro [1 ]
Forner, Alejandro [1 ,2 ]
机构
[1] Univ Barcelona, Hosp Clin Barcelona, August Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona Clin Liver Canc BCLC Grp,Liver Unit, Barcelona, Spain
[2] Network Biomed Res Hepat & Digest Dis CIBERehd, Barcelona, Spain
关键词
Hepatocellular carcinoma; Liver cancer; Screening; Surveillance; Overall survival; Cirrhosis; Liver disease; RANDOMIZED CONTROLLED-TRIAL; CHRONIC HEPATITIS-C; ALPHA-FETOPROTEIN; LIVER-CANCER; CIRRHOTIC-PATIENTS; COST-EFFECTIVENESS; NATURAL-HISTORY; TRANSIENT ELASTOGRAPHY; COMPENSATED CIRRHOSIS; PORTAL-HYPERTENSION;
D O I
10.1016/j.bpg.2016.10.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) appears mainly in patients with underlying liver disease and it is recognized as one of the most important causes of death in this population. Early detection by surveillance has been suggested as an effective tool for reducing cancer-specific mortality and the most accepted strategy is semiannual abdominal ultrasound in those patients at risk of HCC development. The benefit of HCC surveillance is proven by a randomized-controlled study, several prospective or retrospective analyses, and multiple modeling studies and according to the current scientific evidence, surveillance of HCC should be recommended and widely implemented. Major efforts should be done for improving the diagnostic accuracy of the screening tools and for better identifying those patients at risk of HCC development in whom a surveillance program would be cost-effective. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1001 / 1010
页数:10
相关论文
共 68 条
  • [1] Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis
    Andersson, Karin L.
    Salomon, Joshua A.
    Goldie, Sue J.
    Chung, Raymond T.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (12) : 1418 - 1424
  • [2] [Anonymous], 1968, PRINCIPLES PRACTICE, DOI DOI 10.1001/ARCHINTE.162.22.2557
  • [3] [Anonymous], GASTROENTEROLOGY
  • [4] [Anonymous], LIV HEP CANC SCREEN
  • [5] Arguedas MR, 2003, AM J GASTROENTEROL, V98, P679, DOI [10.1016/S0002-9270(02)06049-5, 10.1111/j.1572-0241.2003.07327.x]
  • [6] NATURAL-HISTORY OF SMALL UNTREATED HEPATOCELLULAR-CARCINOMA IN CIRRHOSIS - A MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS OF TUMOR-GROWTH RATE AND PATIENT SURVIVAL
    BARBARA, L
    BENZI, G
    GAIANI, S
    FUSCONI, F
    ZIRONI, G
    SIRINGO, S
    RIGAMONTI, A
    BARBARA, C
    GRIGIONI, W
    MAZZIOTTI, A
    BOLONDI, L
    [J]. HEPATOLOGY, 1992, 16 (01) : 132 - 137
  • [7] Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans
    Block, TM
    Comunale, MA
    Lowman, M
    Steel, LF
    Romano, PR
    Fimmel, C
    Tennant, BC
    London, WT
    Evans, AA
    Blumberg, BS
    Dwek, RA
    Mattu, TS
    Mehta, AS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) : 779 - 784
  • [8] Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis
    Bolondi, L
    Sofia, S
    Siringo, S
    Gaiani, S
    Casali, A
    Zironi, G
    Piscaglia, F
    Gramantieri, L
    Zanetti, M
    Sherman, M
    [J]. GUT, 2001, 48 (02) : 251 - 259
  • [9] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [10] NATURAL-HISTORY OF HEPATOCELLULAR-CARCINOMA IN SPAIN - 5 YEARS EXPERIENCE IN 249 CASES
    CALVET, X
    BRUIX, J
    BRU, C
    GINES, P
    VILANA, R
    SOLE, M
    AYUSO, MD
    BRUGUERA, M
    RODES, J
    [J]. JOURNAL OF HEPATOLOGY, 1990, 10 (03) : 311 - 317